Goldman Sachs downgrades Novartis to sell.

Goldman Sachs downgrades Novartis to sell.

Goldman Sachs Group Inc. has downgraded its rating for Novartis AG (NYSE: NVS) to 'Sell' following a significant increase in the company's stock position. The investment bank, which owned approximately 0.17% of Novartis worth $408.07 million at the end of the first quarter, increased its stake by 60.3% to 3,660,485 shares .

The downgrade comes amidst a mixed outlook among analysts for Novartis, with one "Strong Buy," several "Hold," and some "Sell" ratings. The average target price is set at $124.33 . Goldman Sachs' decision to downgrade Novartis could be influenced by various factors, including recent acquisitions, such as the $1.4 billion deal for Tourmaline Bio, and the company's mixed performance in the biopharmaceutical market .

Additionally, Novartis' stock has shown mixed performance, trading up $1.07 during midday trading on Thursday, reaching $127.62. The company reported $2.42 earnings per share for the quarter, topping analysts' consensus estimates of $2.38 by $0.04 . However, the stock's twelve-month low of $96.06 and high of $130.46 indicate volatility in its performance .

Goldman Sachs' downgrade may signal a shift in investor sentiment towards Novartis, potentially influencing other institutional investors to reassess their positions. As the company continues to navigate its strategic initiatives and market performance, investors will closely monitor any further developments and analyst ratings.

: https://www.marketbeat.com/instant-alerts/filing-goldman-sachs-group-inc-has-40807-million-stock-position-in-novartis-ag-nvs-2025-09-09/
: https://www.mmm-online.com/news/rx-rundown-novo-nordisk-servier-novartis-and-more/